Lab Dx of Cancer, Intro to Hematologic Malignancies, Acute Leukemias Flashcards
PSA
early detection/screening
men over 50, poor specificity for cancer
alpha-fetoprotein
diagnostic, assess for presence of testicular cancer
ER
HER2
KRAS
Predictive: Effective drug therapy
CEA
carcinoembryonic antigen
Post-Therapeutic Monitor: Detect tumor recurrence
colorectal cancer
BRAC1
Risk Stratification: Chance of getting cancer
k-ras mutation
Predicts lack of therapeutic response to a specifc drug
Testing should be done in all pts w/ metastatic colorectal cancer
Absence of MLH-1
raises possibility of inherited tumor susceptibility in the family
CA-125
ovarian cancer screening
can also be elevated in normal post-menopausal women
genetic diseases inc risk of hematologic malignancy
Down syndrome Klinefelter syndrome
Wiskott-Aldrich syndrome
Bloom syndrome Fanconi anemia neuroqbromatosis ataxia telangiectasia
viral infections inc risk of hematologic malignancy
EBV
HTLV
HHV-8
HIV
bacterial infections inc risk of hematologic malignancy
H. pylori
–> gastric MALT lymphoma
most significant tumor suppressor gene
p53
fluorescence in situ hybridization
each normal chromosome produces 2 dots
monosomy –> 1dot
trisomy –> 2dots
flow cytometry
uses Abs labeled to recognize cell surface antigens
most common childhood cancer
ALL
genetic disorders that are risk fx for acute leukemia
Down Klinefelter Turner Neurofibromatosis Fanconi anemia
leukostasis
stasis of blood in cerebral/pulm circulation
blast >50,000
HA, visual change, confusion, stroke, coma (cerebral)
dyspnea, tachypnea, hypoxia
AML>ALL
ALL extra-medullary manifestations
lymphadenopathy
splenomegaly
mediastinal mass
leukemic meningitis rare at dx, CNS = common site of relapse
testes
AML extra-medullary manifestations
leukemic cutis
gingival hypertrophy
chloromas (green tumor of blasts)
ALL metabolic abnormalities
tumor lysis syndrome
AML metabolic abnormalities
hypOkalemia (via renal tubular damage by enzyme released from myeloblasts)
hypOglycemia (artificial finding due to metabolic activity of blasts in blood tube after draw)
WHO dx of AML
> 20% blasts in bone marrow
+ cytogenetic findings